Humana Inc (HUM)
NYSE:HUM
Want to see HUM full AI Analyst Report?
Top Page
Humana
(NYSE:HUM)
Select Model
Select Model
Rating:63Neutral
Price Target:
$321.00
▲(56.48% Upside)
Action:Reiterated
Date:04/29/26
The score is driven primarily by mixed fundamentals: solid growth and manageable leverage but meaningful margin/return compression and choppy cash conversion. Technicals are constructive on trend but look overextended, while valuation and a modest yield offer limited cushion; the earnings call adds some support via reiterated improvement targets but is tempered by cost and reserving headwinds.
Positive Factors
Steady Revenue Growth
Humana's multi-year revenue growth trajectory and positive TTM growth demonstrate durable demand for Medicare Advantage, Part D and Medicaid products. Consistent top-line expansion supports scale advantages in network contracting, pharmacy negotiating leverage and investment in care-management initiatives that improve long-term margins.
Negative Factors
Material Margin Compression
Net margins have compressed substantially, leaving earnings highly sensitive to medical cost swings and funding. With narrow operating cushions, sustainable profitability depends on achieving targeted MA margin improvements; absent durable medical-cost control, returns and capital generation may remain constrained for several years.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Humana's multi-year revenue growth trajectory and positive TTM growth demonstrate durable demand for Medicare Advantage, Part D and Medicaid products. Consistent top-line expansion supports scale advantages in network contracting, pharmacy negotiating leverage and investment in care-management initiatives that improve long-term margins.
Read all positive factors
Humana Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down sales figures for each business unit, indicating which areas are contributing most to growth and where there might be potential for expansion or risk.
Breaks down sales figures for each business unit, indicating which areas are contributing most to growth and where there might be potential for expansion or risk.
Data provided by:
The Fly
The FlyHumana (HUM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.18B
Dividend Yield1.38%
Average Volume (3M)1.68M
Price to Earnings (P/E)4.4
Beta (1Y)0.97
Revenue Growth14.08%
EPS Growth-33.82%
CountryUS
Employees65,680
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Plans
Share Statistics
EPS (TTM)9.38
Shares Outstanding120,061,500
10 Day Avg. Volume1,970,378
30 Day Avg. Volume1,677,647
Financial Highlights & Ratios
PEG Ratio-18.57
Price to Book (P/B)1.75
Price to Sales (P/S)0.24
P/FCF Ratio82.27
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue0.33
Enterprise Value/Gross Profit2.38
Enterprise Value/Ebitda16.02
Forecast
1Y Price Target
$241.18Price Target Upside17.57% Upside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)8.94
Revenue Forecast (FY)$162.40B
Humana Business Overview & Revenue Model
Company Description
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental be...
How the Company Makes Money
Humana primarily makes money by collecting premiums and receiving government payments to provide health insurance benefits, then managing the cost of members’ medical care relative to those payments.
1) Insurance premiums and membership-based pay...
Humana Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed constructive progress on strategic priorities — membership growth, CenterWell expansion, balance sheet improvements, operational transformation, and measured Stars progress — while candidly acknowledging persistent headwinds: medical cost trend outpacing funding, elevated early-year reserves, potential put-option cash exposure, and the need to consider benefit adjustments in 2027. Management emphasized prudence in reserving, disciplined bidding, and multiple levers (operational improvements, M&A, pricing) to meet the 2028 margin objective.Positive Updates
On-Track to Investor Day Commitments
Management reiterated they are on track to meet Investor Day commitments, targeting a sustainable Medicare Advantage margin of at least 3% in 2028 and making progress in 2027.
Negative Updates
Medical Cost Trend Outpacing Program Funding
Management acknowledged medical cost trend continues to outpace program funding despite CMS's improved rate notice, requiring pricing discipline and potential benefit adjustments to protect margins.
Read all updates
Q1-2026 Updates
Positive
Negative
On-Track to Investor Day Commitments
Management reiterated they are on track to meet Investor Day commitments, targeting a sustainable Medicare Advantage margin of at least 3% in 2028 and making progress in 2027.
Read all positive updates
Company Guidance
Humana reiterated that it is “where we expect to be” and is focused on returning to a sustainable individual MA margin of at least 3% by 2028 (with progress in 2027), expects to double individual MA margin in 2026 (adjusted for Stars), and will remain disciplined in pricing and benefit design; operational and capital moves cited include Medicaid growth of ~50,000 lives, CenterWell primary care adding ~110,000 patients (22.5% sequential growth) and the Max Health acquisition, early HEDIS closure ~5% ahead year-over-year on a per‑member basis, IBNR up ~35% sequentially vs ~22% Medicare membership growth, a Q2 MLR guide slightly above ~91%, completion of $1.0B junior subordinated notes in March to fund 2027 maturities, mitigation of >$3.0B in 2026 capital contribution requirements, and a potential Welsh Carson put exposure of roughly $1.0–$1.5B (planned for in the funding plan), while maintaining dividends, limiting buybacks to offset dilution and expecting CenterWell seasonality/operating metrics to normalize through the year.Humana Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
68
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 137.20B | 129.66B | 117.81B | 106.44B | 92.92B | 83.65B |
| Gross Profit | 19.22B | 18.85B | 17.15B | 18.05B | 17.23B | 14.45B |
| EBITDA | 2.85B | 2.91B | 3.25B | 4.73B | 4.81B | 4.46B |
| Net Income | 1.13B | 1.19B | 1.21B | 2.49B | 2.81B | 2.93B |
Balance Sheet | ||||||
| Total Assets | 55.28B | 48.75B | 46.31B | 46.89B | 43.73B | 44.75B |
| Cash, Cash Equivalents and Short-Term Investments | 21.96B | 4.20B | 2.22B | 4.69B | 5.06B | 3.39B |
| Total Debt | 13.99B | 12.94B | 12.26B | 12.27B | 11.75B | 13.22B |
| Total Liabilities | 36.63B | 31.01B | 29.87B | 30.57B | 28.36B | 28.64B |
| Stockholders Equity | 18.58B | 17.66B | 16.38B | 16.26B | 15.31B | 16.08B |
Cash Flow | ||||||
| Free Cash Flow | 1.27B | 375.00M | 2.39B | 2.98B | 3.45B | 920.00M |
| Operating Cash Flow | 1.84B | 921.00M | 2.97B | 3.98B | 4.59B | 2.26B |
| Investing Cash Flow | -594.00M | 2.27B | -2.95B | -3.49B | -1.01B | -6.56B |
| Financing Cash Flow | -549.00M | -1.22B | -2.49B | -856.00M | -1.91B | 3.02B |
Humana Technical Analysis
Neutral
205.14
Price Trends
181.19
Positive
215.65
Negative
238.93
Negative
Market Momentum
5.90
Negative
68.01
Neutral
89.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HUM, the sentiment is Neutral. The current price of 205.14 is above the 20-day moving average (MA) of 184.35, above the 50-day MA of 181.19, and below the 200-day MA of 238.93, indicating a neutral trend. The MACD of 5.90 indicates Negative momentum. The RSI at 68.01 is Neutral, neither overbought nor oversold. The STOCH value of 89.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HUM.
Humana Risk Analysis
Humana disclosed 16 risk factors in its most recent earnings report. Humana reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Humana Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $78.02B | 10.59 | 15.16% | 2.21% | 9.30% | 30.22% | |
75 Outperform | $86.15B | 9.15 | 11.95% | 1.99% | 9.44% | -8.53% | |
74 Outperform | $362.43B | 9.80 | 12.40% | 2.69% | 9.67% | -44.84% | |
63 Neutral | $36.18B | 4.40 | 6.19% | 1.38% | 14.08% | -33.82% | |
63 Neutral | $28.99B | 2.61 | -28.72% | ― | 17.02% | -294.77% | |
55 Neutral | $9.73B | 121.40 | 4.44% | ― | 7.72% | -83.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HUM
Humana
301.35
67.09
28.64%
CNC
Centene
58.70
-3.08
-4.99%
CI
Cigna
294.93
-19.36
-6.16%
MOH
Molina Healthcare
186.80
-138.54
-42.58%
UNH
UnitedHealth
399.09
115.19
40.57%
ELV
Elevance Health
396.71
1.85
0.47%
Humana Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Humana Posts Strong Q1 Results, Affirms 2026 Outlook
Positive
Apr 29, 2026
Humana on April 29, 2026 reported first-quarter 2026 GAAP EPS of $9.83 and adjusted EPS of $10.31, landing at the high end of its guidance range as its Insurance segment posted a slightly better-than-expected benefit ratio of 89.4 percent. The com...
Executive/Board ChangesShareholder Meetings
Humana Shareholders Approve Directors, Auditor and Incentive Plan
Positive
Apr 20, 2026
At Humana Inc.’s regular annual meeting of stockholders held on April 16, 2026, shareholders elected all ten nominees to the board of directors, each to serve until the next annual meeting or until a successor is chosen. The voting showed br...
Business Operations and StrategyExecutive/Board Changes
Humana Expands Board, Elects Robert Field as Director
Positive
Apr 10, 2026
On April 10, 2026, Humana Inc.’s Board of Directors expanded its size from ten to eleven members and elected Robert S. Field as an independent director, with his appointment to take effect immediately following the company’s 2026 Annua...
Private Placements and Financing
Humana Issues $1 Billion Junior Subordinated Notes Offering
Neutral
Mar 9, 2026
On March 5, 2026, Humana entered an underwriting agreement with a syndicate led by Goldman Sachs and J.P. Morgan to issue $1.0 billion of 6.625% fixed-to-fixed rate junior subordinated notes due 2056, sold at par. After underwriting discounts and ...
Business Operations and StrategyFinancial Disclosures
Humana Reaffirms 2026 Earnings Guidance in Investor Meetings
Positive
Mar 2, 2026
Between March 2 and March 31, 2026, Humana’s senior management planned to meet with investors and analysts to discuss the company’s outlook for the year ending December 31, 2026. During these meetings, the company said it would reaffir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.